Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Carbamazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | P2RX4 | Q99571 | 16/20 | 0.74 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.56 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamazepine SCHEMBL29360181 | 1.00 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29433237 | 1.00 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL6477112 | 1.00 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL31685158 | 1.00 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL1421962 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29390487 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL28169915 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29023618 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL5382102 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL27589204 | 0.98 | LMNA (0.96) | LMNATSHRMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 58748 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | 4M THERAPEUTICS INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-12640228-B2 | Polymorphic markers for pharmacogenetic HLA risk alleles | SEMA4 OPCO, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-121558452-B | Sample pretreatment method, kit and detection method for anti-epileptic drug detection | Lianying Yuezhi Scientific Instrument (Wuhan) Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075697-A | SFMBT2 gene and application of bromocriptine in repairing damaged cartilage and preventing and treating osteoarthritis | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12629377-B2 | Lamotrigine oral liquid suspension and use thereof | ROWP IP HOLDING II LLC | 2026-05-19 | — | — | US | claimed |
| CN-122035832-A | Preparation method of graphite nitrogen-pyridine nitrogen co-doped two-dimensional carbon nanomaterial and method for electrochemically screening electron-rich aromatic pollutants | 南开大学 | 2026-05-15 | — | — | CN | claimed |
| US-4436660-A | Process for the production of 5-cyano-and 5-carboxamido-5H-dibenz[b,f]azepines | CIBA-GEIGY CORPORATION (US) | 1984-03-13 | — | — | US | claimed |
| US-4431641-A | AN ANTICONVULSANT DIBENZ/B,F/AZEPINE POTENTIATED BY A VINCAMINE OR PIRACETAM DERIVATIVE | CIBA-GEIGY CORPORATION (US) | 1984-02-14 | — | — | US | claimed |
| US-4409212-A | Method of preventing and treating cerebral insufficiency | CIBA-GEIGY CORPORATION (US) | 1983-10-11 | — | — | US | claimed |
| US-4404366-A | ENZYME CLEAVABLE GLYCOSIDIC LINKAGE | MILES LABORATORIES, INC. (US) | 1983-09-13 | — | — | US | claimed |
| EP-0080341-A2 | Pharmaceutical multiple-units formulation | A/S Alfred Benzon (DK) | 1983-06-01 | — | — | EP | claimed |
| EP-0050589-A1 | Pharmaceutical compositions with an anti-epileptic and anti-neuralgic effect, and process for their manufacture | CIBA-GEIGY AG (CH) | 1982-04-28 | — | — | EP | claimed |
| EP-0044441-A1 | Monoclonal antibodies to drugs, methods for their production and somatic cell hybridomas secreting them | MILES LABORATORIES, INC. (US) | 1982-01-27 | — | — | EP | claimed |
| US-4279992-A | Specific binding assay employing an enzyme-cleavable substrate as label | MILES LABORATORIES, INC. (US) | 1981-07-21 | — | — | US | claimed |
| EP-0029409-A1 | Process for preparing 5-cyano-5H-dibenz(b,f)azepine and 5H-dibenz(b,f)azepine-5-carboxamide | CIBA-GEIGY AG (CH) | 1981-05-27 | — | — | EP | claimed |
| EP-0002436-A1 | A centrifugal clutch with an overspeed relief valve and clutch modulation | CATERPILLAR TRACTOR CO. (US) | 1979-06-27 | — | — | EP | claimed |